midazolam has been researched along with Panic Disorder in 5 studies
Midazolam: A short-acting hypnotic-sedative drug with anxiolytic and amnestic properties. It is used in dentistry, cardiac surgery, endoscopic procedures, as preanesthetic medication, and as an adjunct to local anesthesia. The short duration and cardiorespiratory stability makes it useful in poor-risk, elderly, and cardiac patients. It is water-soluble at pH less than 4 and lipid-soluble at physiological pH.
midazolam : An imidazobenzodiazepine that is 4H-imidazo[1,5-a][1,4]benzodiazepine which is substituted by a methyl, 2-fluorophenyl and chloro groups at positions 1, 6 and 8, respectively.
Panic Disorder: A type of anxiety disorder characterized by unexpected panic attacks that last minutes or, rarely, hours. Panic attacks begin with intense apprehension, fear or terror and, often, a feeling of impending doom. Symptoms experienced during a panic attack include dyspnea or sensations of being smothered; dizziness, loss of balance or faintness; choking sensations; palpitations or accelerated heart rate; shakiness; sweating; nausea or other form of abdominal distress; depersonalization or derealization; paresthesias; hot flashes or chills; chest discomfort or pain; fear of dying and fear of not being in control of oneself or going crazy. Agoraphobia may also develop. Similar to other anxiety disorders, it may be inherited as an autosomal dominant trait.
Excerpt | Relevance | Reference |
---|---|---|
" low-dose intranasal midazolam in five patients diagnosed with DSM-III-R panic disorder." | 9.07 | The use of low-dose intranasal midazolam to treat panic disorder: a pilot study. ( Clary, C; Dever, AI; Mandos, LA; Schweizer, E, 1992) |
" low-dose intranasal midazolam in five patients diagnosed with DSM-III-R panic disorder." | 5.07 | The use of low-dose intranasal midazolam to treat panic disorder: a pilot study. ( Clary, C; Dever, AI; Mandos, LA; Schweizer, E, 1992) |
" Combined, chronic administration of these doses yielded a sustained synergism in motor performance impairment, which contrasted with the antagonism usually found between the benzodiazepines and methylxanthines when performance is evaluated by psychomotor tests not requiring fine motor control." | 1.28 | Sustained synergism by chronic caffeine of the motor control deficit produced by midazolam. ( Falk, JL; Lau, CE, 1991) |
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 2 (40.00) | 18.2507 |
2000's | 2 (40.00) | 29.6817 |
2010's | 1 (20.00) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
Strauss, CV | 1 |
Vicente, MA | 1 |
Zangrossi, H | 3 |
de Paula Soares, V | 1 |
Bueno, CH | 1 |
Nogueira, RL | 1 |
Soares, VP | 1 |
Viana, MB | 1 |
Lau, CE | 1 |
Falk, JL | 1 |
Schweizer, E | 1 |
Clary, C | 1 |
Dever, AI | 1 |
Mandos, LA | 1 |
1 trial available for midazolam and Panic Disorder
Article | Year |
---|---|
The use of low-dose intranasal midazolam to treat panic disorder: a pilot study.
Topics: Administration, Intranasal; Adult; Double-Blind Method; Female; Humans; Male; Midazolam; Panic Disor | 1992 |
4 other studies available for midazolam and Panic Disorder
Article | Year |
---|---|
Activation of 5-HT1A receptors in the rat basolateral amygdala induces both anxiolytic and antipanic-like effects.
Topics: 8-Hydroxy-2-(di-n-propylamino)tetralin; Amygdala; Animals; Anti-Anxiety Agents; Anxiety; Dark Adapta | 2013 |
Stimulation of 5-HT1A or 5-HT2A receptors in the ventrolateral periaqueductal gray causes anxiolytic-, but not panicolytic-like effect in rats.
Topics: Analysis of Variance; Animals; Anti-Anxiety Agents; Anxiety Disorders; Avoidance Learning; Escape Re | 2009 |
Panicolytic-like effect induced by the stimulation of GABAA and GABAB receptors in the dorsal periaqueductal grey of rats.
Topics: Analysis of Variance; Animals; Anxiety Disorders; Avoidance Learning; Baclofen; Behavior, Animal; Ca | 2005 |
Sustained synergism by chronic caffeine of the motor control deficit produced by midazolam.
Topics: Animals; Caffeine; Discrimination Learning; Drug Synergism; Male; Midazolam; Panic Disorder; Psychom | 1991 |